Cyclin-dependent kinase 1/cyclin B1 phosphorylates varicella-zoster virus IE62 and is incorporated into virions.
Varicella-zoster virus (VZV), an alphaherpesvirus restricted to humans, infects differentiated cells in vivo, including T lymphocytes, keratinocytes, and neurons, and spreads rapidly in confluent cultured dermal fibroblasts (HFFs). In VZV-infected HFFs, atypical expression of cyclins D3 and B1 occurs along with the induction of cyclin-dependent kinase (CDK) activity. A specific CDK1 inhibitor blocked VZV spread, indicating an important function for this cellular kinase in VZV replication. CDK activity assays of infected cells revealed a large viral phosphoprotein that was identified as being the major immediate-early transactivator, IE62. Since IE62 colocalized with CDK1/cyclin B1 by confocal microscopy, we investigated whether this cellular kinase complex interacts with IE62. Using recombinant fragments of IE62 spanning the entire amino acid sequence, we found that purified CDK1/cyclin B1 phosphorylated IE62 at residues T10, S245, and T680 in vitro. Immunoprecipitation of cyclin B1 from VZV-infected HFFs indicated that IE62 was included in the complex within infected cells. The full-length IE62 protein, obtained by immunoprecipitation from infected cells, was also phosphorylated by purified CDK1/cyclin B1. Based on IE62/CDK1/cyclin B1 colocalization near viral assembly regions, we hypothesized that these cellular proteins could be incorporated into VZV virions with IE62. Purified virions were analyzed by immunoblotting for the presence of CDK1 and cyclin B1, and active CDK1 and cyclin B1 were present in the VZV tegument with IE62 and were sensitive to detergent treatment. Thus, IE62 is a substrate for CDK1/cyclin B1, and virions could deliver the active cellular kinase to nondividing cells that normally do not express it.
Leisenfelder
Stacey A
SA
Department of Microbiology and Immunology, SUNY Upstate Medical University, 750 East Adams St., Syracuse, NY 13210, USA.
Kinchington
Paul R
PR
Moffat
Jennifer F
JF
D016203:CDC2 Protein Kinase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002478:Cells, Cultured; D019926:Cyclin B / Q000378:metabolism*; D056744:Cyclin B1; D006056:Golgi Apparatus / Q000378:metabolism; D014645:Herpesvirus 3, Human / Q000378:metabolism*; D006801:Humans; D017874:Immediate-Early Proteins / Q000235:genetics / Q000378:metabolism*; D010766:Phosphorylation; D011485:Protein Binding; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism*; D014759:Viral Envelope Proteins / Q000235:genetics / Q000378:metabolism*; D014771:Virion / Q000187:drug effects / Q000378:metabolism*; D053586:Virus Internalization; D014779:Virus Replication
C534699:CCNB1 protein, human; D019926:Cyclin B; D056744:Cyclin B1; C074221:IE62 protein, Human herpesvirus 3; D017874:Immediate-Early Proteins; D047428:Protein Kinase Inhibitors; D015534:Trans-Activators; D014759:Viral Envelope Proteins; D016203:CDC2 Protein Kinase
J Med Virol. 2003;70 Suppl 1:S90-4
12627495
Virus Res. 1998 Aug;56(2):191-7
9783468
Microbiol Mol Biol Rev. 2007 Jun;71(2):398-411
17554050
J Virol. 2001 Sep;75(18):8854-8
11507231
EMBO J. 1991 Feb;10(2):397-406
1846804
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11969-74
9751774
Virology. 2005 Jul 5;337(2):304-11
15913699
J Biol Chem. 1999 Apr 23;274(17):11977-86
10207019
J Virol. 1989 Sep;63(9):3912-8
2548005
J Virol. 2003 May;77(10):6062-5
12719598
J Virol. 1994 Mar;68(3):1350-9
8107200
J Virol. 2005 Jul;79(13):8348-60
15956580
J Virol. 2004 Jun;78(11):5856-66
15140983
BMC Bioinformatics. 2004 Jun 22;5:79
15212693
J Virol. 2001 Oct;75(19):9106-13
11533174
J Virol. 1996 Nov;70(11):7734-43
8892894
J Virol. 2005 Sep;79(17):11501-6
16103201
J Virol. 1992 May;66(5):2709-16
1313896
Virology. 2000 Jul 5;272(2):375-81
10873781
J Virol. 2006 Feb;80(3):1332-9
16415010
J Virol. 2003 May;77(10):5607-20
12719553
J Virol. 2007 Jan;81(2):977-90
17079291
J Virol. 1997 Jun;71(6):4832-7
9151881
Cell. 1998 Sep 18;94(6):783-93
9753325
J Cell Biol. 2001 Mar 5;152(5):945-58
11238451
J Biol Chem. 2002 Jun 7;277(23):21050-60
11912195
J Virol. 1995 Jul;69(7):4274-82
7769688
J Virol. 2005 Oct;79(20):12921-33
16188994
Cell Mol Life Sci. 2004 Dec;61(24):3047-56
15583866
J Virol. 1998 Sep;72(9):7108-14
9696804
J Virol. 1996 Sep;70(9):6097-105
8709233
Mol Cell Biol. 2004 Jul;24(13):5875-86
15199143
J Virol. 2005 Apr;79(8):4952-64
15795281
J Virol. 2000 Mar;74(5):2107-20
10666240
Biochim Biophys Acta. 2004 Mar 11;1697(1-2):225-31
15023363
J Gen Virol. 2003 Nov;84(Pt 11):2957-2967
14573800
J Virol. 1996 Feb;70(2):1061-71
8551564
J Virol. 1992 Jan;66(1):359-66
1309252
J Infect Dis. 1998 Nov;178 Suppl 1:S16-21
9852967
J Biol Chem. 2003 Dec 19;278(51):50956-60
14506259
J Virol. 1994 Oct;68(10):6372-90
8083976
Virology. 2002 Oct 10;302(1):71-82
12429517
Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6958-62
1495986
J Virol. 2004 Mar;78(6):2853-62
14990704
J Virol. 2007 Jan;81(2):761-74
17079304
J Virol. 2002 May;76(9):4666-70
11932435
Cell. 2004 Dec 29;119(7):915-26
15620351
J Virol. 2007 May;81(10):5305-14
17344282
J Virol. 2006 Jun;80(11):5577-87
16699039
J Biol Chem. 2003 Sep 26;278(39):38068-75
12855699
J Biol Chem. 1995 Nov 24;270(47):28419-24
7499347
J Virol. 1996 Feb;70(2):1050-60
8551563
J Virol. 1999 Feb;73(2):1468-78
9882353
J Virol. 1999 Feb;73(2):1320-30
9882337
J Med Virol. 2003;70 Suppl 1:S95-102
12627496
J Virol. 2006 Feb;80(4):1710-23
16439528
J Virol. 2000 Mar;74(5):2265-77
10666257
J Virol. 2006 Jan;80(1):494-504
16352573
J Biol Chem. 2005 Aug 12;280(32):29135-43
15955820